Novo Nordisk Xultophy® was a new breakthrough treatment option that could provide type 2 diabetes patients uncontrolled on glargine with the following unique combination of benefits: significant HbA1c reduction, weight loss, and a lower rate of hypoglycaemia vs glargine. In addition, Xultophy® was the first-ever basal insulin and GLP-1 analogue in one pen.

I was part of the creative pitch team that help win the business for HAVAS H4B Chelsea. The account revenued $3.5 million for the agency.

I lead the art team for the global account.

The global campaign “Stair arrow” showed patients lowering their HbA1c, weight, and hypoglycaemia on signage on the stairs, to reach their treatment goals in the treatment of diabetes.

The range of projects developing the brand included campaign development, user experience, branding guidelines, convention design, logo design, animation, photoshoots, print material, customer experience and social media.